New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 25, 2014
05:55 EDTHD, HD, M, M, TOL, TOL, TMUS, TMUS, ARIA, ARIA, VSI, VSI, BLMN, BLMN, FE, FE, HFC, HFCNotable companies reporting before today's open
Notable companies reporting before today's open, with earnings consensus, include Home Depot (HD), consensus 71c; Macy's (M), consensus $2.17; Toll Brothers (TOL), consensus 18c; T-Mobile US (TMUS), consensus (13c); ARIAD Pharmaceuticals (ARIA), consensus (47c); Vitamin Shoppe (VSI), consensus 38c; Bloomin' Brands (BLMN), consensus 26c; FirstEnergy (FE), consensus 69c; HollyFrontier (HFC), consensus 20c.
News For HD;M;TOL;TMUS;ARIA;VSI;BLMN;FE;HFC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
January 15, 2015
09:01 EDTTMUST-Mobile introduces Simply Prepaid monthly plan
T-Mobile has introduced Simply Prepaid. The Un-carrier’s new monthly prepaid plan delivers unlimited data, talk and text with 4G LTE data buckets starting as low as $40 a month − all on T-Mobile’s Data Strong nationwide 4G LTE network. Simply Prepaid is the perfect complement to T-Mobile’s wildly popular Simple Choice plan. Simply Prepaid dealer locations and all other authorized retailers starting January 25.
07:38 EDTTOLToll Brothers initiated with an Equal Weight at Morgan Stanley
Subscribe for More Information
05:53 EDTHFCHollyFrontier management to meet with Guggenheim
Subscribe for More Information
January 14, 2015
09:04 EDTTMUST-Mobile says Mobile Monney customers to get $20 credit
T-Mobile CEO John Legere announced via Twitter that T-Mobile customers with Mobile Money who set up and receive a direct deposit of their tax refund onto their registered T-Mobile Visa Prepaid Card will get a $20 credit.
07:20 EDTARIAARIAD sees product revenues reaching over $400M in 2018
For 2014, sees product and license revenue at $100M, R&D expenses $120M. For 2015, plans to accelerate Iclusig sales in U.S. and Europe, initiate key Iclusig trials, secure broad partnership for brigatinib, file for Iclusig approval in Japan with Otsuka, file IND for new development candidate AP32788. Comments from slides that will be presented at the JP Morgan Healthcare Conference.
January 13, 2015
14:41 EDTTMUST-Mobile management to meet with Evercore ISI
Meeting to be held in New York on January 15 hosted by Evercore ISI.
12:48 EDTTOLOn The Fly: Midday Wrap
Subscribe for More Information
11:50 EDTTOLKB Home comments hit shares of Homebuilders
Shares of companies in the Homebuilders space declined after KB Home (KBH) said on its earnings conference call that it will not meet its housing gross profit margin goal in 2015. KB cautioned that there is "still much work to do be done" to achieve its financial goals going forward. The homebuilder noted that as Q4 progressed, demand in some of its markets softened. It expects gross margins in Q1 to be down "significantly" from the year-ago period. Publicly traded companies in the space include Beazer Homes (BZH), D.R. Horton (DHI), Hovnanian (HOV), Lennar (LEN), M.D.C. Holdings (MDC), PulteGroup (PHM), Ryland Group (RYL) and Toll Brothers (TOL). The stocks moved lower following KB's comments.
11:44 EDTTOLHomebuilders decline after KB says won't hit 2015 housing margin goal
Subscribe for More Information
10:00 EDTFEOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:00 EDTMMacy's names RLJ Lodging Trust CFO Leslie Hale to board of directors
Subscribe for More Information
07:40 EDTARIAARIAD reports net sales of Iclusig of approx. $55M for year ended Dec. 31
Subscribe for More Information
07:39 EDTARIAARIAD announces key strategic objectives for 2015
ARIAD Pharmaceuticals announced its key strategic objectives for 2015, details of which will be presented at the 33rd Annual J.P. Morgan Healthcare Conference on January 14, 2015 in San Francisco, California. These objectives are focused on expanded commercial, research and development, and new business development initiatives that together are expected to lead ARIAD to sustained profitability beginning in 2018 without the need for additional equity capital to fund its operations. ARIAD management will provide detail on its corporate strategy for the next several years. This new focus includes: Expanding the global commercial opportunity for Iclusig through a Japan/Asia partnership with Otsuka Pharmaceutical Co., Ltd., and additional regional distributorships, Leveraging its existing commercial infrastructure and investment, particularly in Europe, Securing a broad co-development and co-commercialization partnership for brigatinib, or AP26113, that will accelerate the study of brigatinib in earlier lines of treatment, Investing in three randomized clinical trials to evaluate Iclusig in earlier lines of treatment and potentially to expand its addressable market, Advancing its new development candidate, AP32788, into the clinic, and Achieving sustained profitability in 2018 by reaching global product revenue of more than $400M. Three key Iclusig clinical trials will begin in 2015 including a randomized, Phase 3 trial in patients with chronic-phase CML who have experienced failure after imatinib therapy. This second-line, global trial will evaluate two doses of Iclusig vs. the standard dose of nilotinib. The primary endpoint of the trial will be major molecular response by 12 months. The trial is expected to open to patient enrollment in the second half of 2015 and will be integral to potentially expanding Iclusig into earlier lines of treatment. We expect that approximately 500 patients will be enrolled in this trial. ARIAD says "In a major strategic shift for ARIAD, we expect to secure a broad partnership in 2015 to co-develop and co-commercialize brigatinib. In doing so, we will continue to leverage our existing infrastructure and capabilities, allowing us to accelerate the start of a randomized, first-line trial of brigatinib vs. crizotinib. A partnership will also provide for the exploration of new combination therapies in lung cancer that include brigatinib potentially with other approved and unapproved medicines." The company comments, "We expect to achieve profitability in 2018 through revenue growth and strategic partnerships over the next three years. This includes Iclusig revenue growth in the U.S. and in Europe, as well as Iclusig revenue from Japan and new geographies. We also anticipate increased cash flow from brigatinib revenue and partnership payments during this time period. We expect approval of Iclusig in Canada and Israel in 2015 and in Japan in 2016."
06:31 EDTFEFirstEnergy downgraded to Sell from Neutral at Goldman
Goldman downgraded FirstEnergy to Sell based on relative valuation and risk to consensus estimates. Price target is $36.
January 12, 2015
10:00 EDTTOLOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:19 EDTBLMNMorgan Stanley events at 17th Annual ICR XChange Conference
Company Meetings to be held at the 17th Annual ICR XChange Conference in Orlando, Florida on January 12-13.
08:50 EDTTOLToll Brothers downgraded at KeyBanc
Subscribe for More Information
06:52 EDTTOLToll Brothers downgraded to Hold from Buy at KeyBanc
Subscribe for More Information
06:35 EDTMObama to press for law requiring disclosure of hacking, NY Times says
Subscribe for More Information
06:06 EDTTMUSSoftcard cuts 60 employees in restructuring, Re/code reports
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use